Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission
published 28.07.2020 15:00
The company's vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC).
Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.
This vaccine technology was invented by a research team from Cleveland Clinic, led by Dr. Vincent Tuohy, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute.
SAN JOSE, Calif., July 28, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its prophylactic breast cancer vaccine is making progress towards clinical trials.
Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.